share_log

8-K: CLENE REPORTS Third QUARTER 2024 FINANCIAL RESULTS AND RECENT OPERATING HIGHLIGHTS

8-K: CLENE REPORTS Third QUARTER 2024 FINANCIAL RESULTS AND RECENT OPERATING HIGHLIGHTS

8-K:CLENE公布2024年第三季度财务业绩和近期经营亮点
美股SEC公告 ·  2024/11/13 08:07

Moomoo AI 已提取核心信息

Clene reported Q3 2024 financial results with cash and equivalents of $14.6M as of September 30, 2024. The company met with FDA on November 1 to discuss potential accelerated approval pathway for its ALS treatment CNM-Au8, with meeting minutes pending. Research and development expenses decreased to $4.5M from $6.0M year-over-year, while G&A expenses declined to $3.4M from $3.7M.The company completed a $7.3M registered direct offering in October 2024 and amended its debt agreement with Avenue Capital to defer principal payments and extend maturity to Q2 2025. These financial moves are expected to fund operations into Q1 2025. Net loss for Q3 2024 was $8.0M ($1.22 per share) compared to $2.4M ($0.38 per share) in Q3 2023.In corporate developments, Clene implemented a 1-for-20 reverse stock split in July to regain Nasdaq compliance. The company also presented the design for RESTORE-ALS, its potential confirmatory Phase 3 clinical trial of CNM-Au8 30mg, at the 2024 Annual Northeast ALS Consortium.
Clene reported Q3 2024 financial results with cash and equivalents of $14.6M as of September 30, 2024. The company met with FDA on November 1 to discuss potential accelerated approval pathway for its ALS treatment CNM-Au8, with meeting minutes pending. Research and development expenses decreased to $4.5M from $6.0M year-over-year, while G&A expenses declined to $3.4M from $3.7M.The company completed a $7.3M registered direct offering in October 2024 and amended its debt agreement with Avenue Capital to defer principal payments and extend maturity to Q2 2025. These financial moves are expected to fund operations into Q1 2025. Net loss for Q3 2024 was $8.0M ($1.22 per share) compared to $2.4M ($0.38 per share) in Q3 2023.In corporate developments, Clene implemented a 1-for-20 reverse stock split in July to regain Nasdaq compliance. The company also presented the design for RESTORE-ALS, its potential confirmatory Phase 3 clinical trial of CNM-Au8 30mg, at the 2024 Annual Northeast ALS Consortium.
Clene公布了截至2024年9月30日的第三季度财务结果,截至时现金及现金等价物达1460万美元。公司于11月1日与FDA会面,讨论ALS治疗药物CNm-Au8的潜在加速批准路径,会议纪要尚待发布。研发费用同比减少至450万美元,从600万美元减少,而一般和行政费用则从370万美元减少至340万美元。公司在2024年10月完成了一项730万美元的注册直接发行,并与Avenue Capital修订了债务协议,以推迟本金还款并将到期延长至2025年第二季度。这些财务举措预计将为运营提供资金,延续到2025年第一季度。2024年第三季度净亏损为800万美元(每股1.22美元),而2023年第三季度为240万美元(每股0.38美元)。在公司发展方面,Clene于7月实施了1比20的反向股票拆分,以恢复纳斯达克合规性。公司还在2024年年度东北ALS协会上展示了其CNm-Au8 30毫克的潜在确认性三期临床试验RESTORE-ALS的设计。
Clene公布了截至2024年9月30日的第三季度财务结果,截至时现金及现金等价物达1460万美元。公司于11月1日与FDA会面,讨论ALS治疗药物CNm-Au8的潜在加速批准路径,会议纪要尚待发布。研发费用同比减少至450万美元,从600万美元减少,而一般和行政费用则从370万美元减少至340万美元。公司在2024年10月完成了一项730万美元的注册直接发行,并与Avenue Capital修订了债务协议,以推迟本金还款并将到期延长至2025年第二季度。这些财务举措预计将为运营提供资金,延续到2025年第一季度。2024年第三季度净亏损为800万美元(每股1.22美元),而2023年第三季度为240万美元(每股0.38美元)。在公司发展方面,Clene于7月实施了1比20的反向股票拆分,以恢复纳斯达克合规性。公司还在2024年年度东北ALS协会上展示了其CNm-Au8 30毫克的潜在确认性三期临床试验RESTORE-ALS的设计。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息